Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 6/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789904 | 0.84 | PPARG (0.35) | HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL6933096 | 0.84 | METAP1 (0.44) | — | |
| SCHEMBL9142278 | 0.84 | AKR1B1 (0.45) | ALDH1A1GLACES2HSD17B1PBRM1 | |
| SCHEMBL6931403 | 0.82 | HPGD (0.34) | HSP90AB1ALDH1A1GAAKDM4E | |
| SCHEMBL11848574 | 0.81 | HTT (0.38) | ALDH1A1 | |
| SCHEMBL6936226 | 0.81 | METAP1 (0.40) | HSP90AB1ALDH1A1GAAKDM4EGFER | |
| SCHEMBL6936638 | 0.81 | HSP90AB1 (0.36) | HSP90AB1ALDH1A1GAAGFER | |
| SCHEMBL6932963 | 0.77 | GAA (0.40) | HSP90AB1GAA | |
| SCHEMBL11852017 | 0.76 | NAMPT (0.39) | — | |
| SCHEMBL9145583 | 0.73 | ALOX5AP (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0910380-B1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6403831-B1 | 5,6-DIFLUORO-2-METHYL-1-(3,4,5-TRIMETHOXY-BENZYLIDENE)-3-(N-BE NZYL)-INDENYL ACETAMIDE; ANTITUMOR AND ANTICARCINOGENIC AGENT USED TO TREAT PRECANCEROUS LESIONS | CELL PATHWAYS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-0910380-A4 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6121321-A | IN CARRIER | CELL PATHWAYS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6063818-A | Substituted benzylidene indenyl formamides, acetamides and propionamides | CELL PATHWAYS INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0910380-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | Cell Pathways, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5776962-A | Lactone compounds for treating patient with precancerous lesions | CELL PATHWAYS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5420289-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS AND CYTOPROTECTIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| US-5229516-A | Antiinflammatory agents, antiallergens and cytoprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0502106-A1 | SUBSTITUTED INDOLE-, INDENE-, PYRANOINDOLE- AND TETRAHYDROCARBAZOLE- ALKANOIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-09 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991006537-A2 | SUBSTITUTED INDOLE-, INDENE-, PYRANOINDOLE- AND TETRAHYDROCARBAZOLE- ALKANOIC ACID DERIVATIVES AS INHIBITORS OF PLA2 AND LIPOXYGENASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | HSP90AB1 4464/4885EGFR 1583/4885ALDH1A1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.